Glycotope GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.glycotope.com

Clinical Trials

Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor, Adult

First Posted Date: 2017-12-04

Last Posted Date: 2021-07-12

Lead Sponsor: Glycotope GmbH

Target Recruit Count: 50

Registration Number: NCT03360734

Locations: 🇪🇸
Glycotope-contracted research facility, Barcelona, Spain

CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: Cetuximab
Drug: CetuGEX™
Drug: Chemotherapy

First Posted Date: 2014-02-03

Last Posted Date: 2021-11-02

Lead Sponsor: Glycotope GmbH

Target Recruit Count: 240

Registration Number: NCT02052960

Locations: 🇷🇴
Glycotope-contracteed Research Facility, Timisoara, Romania
🇪🇸
Glycotope-contracted Research Facility, Valencia, Spain
🇮🇹
Gycotope-contracted Research Facility, Milan, Italy

and more 1 locations

PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

Phase 2

Completed

Conditions: Primary Peritoneal Cancer
Fallopian Tube Cancer
Ovarian Epithelial Cancer Recurrent

Interventions: Drug: Placebo
Drug: PankoMab-GEX

First Posted Date: 2013-07-15

Last Posted Date: 2020-10-22

Lead Sponsor: Glycotope GmbH

Target Recruit Count: 216

Registration Number: NCT01899599

Locations: 🇬🇧
Investigator, Sutton, United Kingdom

Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®

Phase 2

Completed

Conditions: Infertility

Interventions: Drug: Follitropin Epsilon
Drug: Follitropin Alfa

First Posted Date: 2013-02-18

Last Posted Date: 2021-05-07

Lead Sponsor: Glycotope GmbH

Target Recruit Count: 267

Registration Number: NCT01794208

Locations: 🇭🇺
Glycotope Investigational Site, Tapolca, Hungary
🇩🇪
Glycotope Investigational Medical Director, Bielefeld, Germany

Multiple Dose FSH-GEX(TM) in Healthy Volunteers

Phase 1

Completed

Conditions: Female Infertility

Interventions: Drug: recombinant FSH
Drug: Placebo
Drug: FSH-GEX™
Drug: urinary FSH

First Posted Date: 2011-11-22

Last Posted Date: 2021-05-07

Lead Sponsor: Glycotope GmbH

Target Recruit Count: 57

Registration Number: NCT01477073

Locations: 🇳🇱
Glycotope Investigational Site, Groningen, Netherlands

TrasGEX™: Phase 1 Study in Cancer Patients

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: TrasGEX™

First Posted Date: 2011-08-04

Last Posted Date: 2021-05-07

Lead Sponsor: Glycotope GmbH

Target Recruit Count: 37

Registration Number: NCT01409343

Locations: 🇨🇭
Glycotope Investigational Site, Bellinzona, Switzerland

Single Dose FSH-GEX™ in Healthy Volunteers

Phase 1

Completed

Conditions: Female Infertility

Interventions: Drug: FSH-GEX™
Drug: Gonal-f
Drug: Bravelle
Drug: Placebo

First Posted Date: 2011-05-17

Last Posted Date: 2021-05-11

Lead Sponsor: Glycotope GmbH

Target Recruit Count: 19

Registration Number: NCT01354886

Locations: 🇳🇱
Glycotope Investigational Site, Groningen, Netherlands

CetuGEX™: Phase 1 Study in Cancer Patients

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: CetuGEX™

First Posted Date: 2010-10-18

Last Posted Date: 2021-05-25

Lead Sponsor: Glycotope GmbH

Target Recruit Count: 41

Registration Number: NCT01222637

Locations: 🇨🇭
Glycotope Investigational Site, Bellinzona, Switzerland

PankoMab-GEX™: Phase 1 Dose Escalation Study

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: PankoMab-GEX™

First Posted Date: 2010-10-18

Last Posted Date: 2021-05-20

Lead Sponsor: Glycotope GmbH

Target Recruit Count: 74

Registration Number: NCT01222624

Locations: 🇨🇭
Glycotope Investigational Site, Bellinzona, Switzerland

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy